Welcome to our dedicated page for Delcath Sys news (Ticker: DCTH), a resource for investors and traders seeking the latest updates and insights on Delcath Sys stock.
Delcath Systems, Inc. develops interventional oncology products for primary and metastatic liver cancers. Its core products include HEPZATO KIT, a melphalan and Hepatic Delivery System combination product approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma, and CHEMOSAT Hepatic Delivery System for Melphalan used in percutaneous hepatic perfusion.
Recurring news covers quarterly operating results, HEPZATO KIT and CHEMOSAT revenue, clinical publications from studies such as FOCUS and CHOPIN, presentations at oncology and interventional radiology meetings, guideline recognition, and studies of melphalan-based percutaneous hepatic perfusion in liver-dominant cancers. Company updates also address FDA-approved product status, European clinical practice references, and capital actions such as common-stock repurchases.
Delcath Systems has announced a retrospective study revealing a 59.4% objective response rate and 89.1% disease control rate in metastatic uveal melanoma patients treated with the CHEMOSAT system. The study, conducted in Europe from 2014 to 2019, included 101 patients. Results indicate that complete, partial, or stable disease correlates with improved survival, with a median overall survival of 20 months. Notably, the study supports the efficacy of PHP in managing liver-dominant metastatic cancers.
Delcath Systems, Inc. (Nasdaq: DCTH) has announced a conference call on August 8, 2022, at 8:30 AM Eastern Time to discuss its second-quarter results ending June 30, 2022. The company specializes in interventional oncology for liver cancer treatment. Interested participants can join by calling in or through a webcast link. Following the call, a replay will be available until August 15, 2022, using specific access codes. Delcath's proprietary systems, HEPZATO and CHEMOSAT, are designed to deliver targeted chemotherapy for liver cancers.
Delcath Systems, Inc. (Nasdaq: DCTH) announced the closing of a private placement, raising gross proceeds of approximately $5.0 million. The offering included the sale of 690,954 shares of common stock at $3.98 each and 566,751 pre-funded warrants priced at $3.97, with an exercise price of $0.01. Proceeds will be utilized for working capital and corporate purposes. The securities are not registered and cannot be offered without prior SEC registration. Delcath is focused on interventional oncology treatments for liver cancers through its proprietary systems.
Delcath Systems, Inc. (Nasdaq: DCTH) announced a securities purchase agreement for a private placement to accredited investors, aiming to raise approximately $5.0 million. The company will sell 690,954 shares of common stock at $3.98 per share or 566,761 pre-funded warrants at $3.97 each, with an exercise price of $0.01. The proceeds will support working capital and other corporate purposes. The transaction is expected to close around July 20, 2022, pending customary conditions.
Delcath Systems (Nasdaq: DCTH) announced promising initial results from the Phase 1b CHOPIN trial, where 85.7% showed Best Overall Response and a 100% Disease Control Rate in patients with advanced uveal melanoma. The median progression-free survival reached 22.4 months with all seven patients alive at follow-up. Additionally, updates on the FOCUS trial revealed consistent interim efficacy data, while a quality of life analysis presented no significant overall changes post-treatment. These results underline the potential of Delcath's percutaneous hepatic perfusion therapy as a viable option for challenging cancer cases.
Delcath Systems reported first-quarter 2022 results, highlighting a net loss of $8.2 million, up from $6.7 million year-over-year. Total revenue remained static at $0.3 million, primarily from CHEMOSAT sales in Europe. R&D expenses increased to $4.2 million, while SG&A expenses rose to $3.6 million. Notably, the company plans to file an NDA for HEPZATO in Q3 2022 following a pre-NDA meeting with the FDA. Additionally, data from a recent study showed a hepatic disease control rate of 88.9% for CHEMOSAT among uveal melanoma patients.
Delcath Systems, Inc. (Nasdaq: DCTH) announced the acceptance of a poster presentation for the FOCUS Phase 3 Trial results at the upcoming ASCO 2022 Annual Meeting in Chicago, running from June 3-7, 2022. The session will focus on the use of Percutaneous Hepatic Perfusion (PHP) with Melphalan in patients with liver metastases from ocular melanoma. The presentation, led by Dr. Jonathan Zager, is scheduled for June 6, 2022.
Delcath's PHP system is designed for targeted high-dose chemotherapy delivery to the liver, addressing unresectable hepatic-dominant metastatic ocular melanoma.
Delcath Systems, a leader in interventional oncology, announced a conference call to discuss its Q1 2022 financial results. The event is scheduled for May 10, 2022, at 8:30 AM ET. Participants can join by dialing in or via webcast. Delcath’s proprietary PHP system delivers high-dose chemotherapy specifically for liver cancers, including metastatic ocular melanoma, under the brand names HEPZATO in the U.S. and CHEMOSAT in Europe. This innovative approach minimizes systemic exposure while targeting cancer effectively, highlighting the company's commitment to advancing cancer treatment.
Delcath Systems, traded as DCTH, will participate in the Canaccord Genuity Horizons in Oncology Conference on April 14, 2022, at 3:00 PM ET. The event will feature a fireside chat and management will engage in virtual one-on-one meetings. Delcath focuses on treating liver cancers using its proprietary percutaneous hepatic perfusion (PHP) system, currently under development in the U.S. as HEPZATO KIT for metastatic ocular melanoma. In Europe, the PHP system is approved as CHEMOSAT to treat various liver cancers.
Delcath Systems, focused on interventional oncology, will participate in the Lytham Partners Spring 2022 Investor Conference. Key events include a presentation on April 4, 2022, at 11:00am ET, and a panel discussion on April 5, 2022, at 2:00pm ET, addressing technologies in cancer treatment. The company is known for its proprietary percutaneous hepatic perfusion system aimed at treating liver cancers, notably under the names HEPZATO in the U.S. and CHEMOSAT in Europe.